MIAMI, FL -- (MARKET WIRE) -- November 07, 2006 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”) announced today that it has submitted a Marketing Authorization Application (“MAA”) to the European Medicines Evaluation Agency (“EMEA”) to market orBec® (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease (“GI GVHD”), the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation in cancer patients. The MAA will be reviewed under the centralized licensing procedure, which, if approval is granted, provides a marketing license valid in all 25 member states of the European Union. Review of the application will be coordinated by the EMEA.
